Successful treatment of two cases with Philadelphia-chromosome positive acute lymphoblastic leukemia who relapsed after allogeneic stem cell transplantation and the treatments with novel immunotherapies and ponatinib

References

• Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24(3):460–466. doi:10.1200/JCO.2005.03.2177
   PubMed Web of Science ®Google Scholar
• Sugiura I, Doki N, Hata T, et al. Dasatinib-based 2-step induction for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Adv. 2022;6(2):624–636. doi:10.1182/bloodadvances.2021004607
   PubMed Web of Science ®Google Scholar
• Jabbour E, Haddad FG, Short NJ, et al. Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-from intensive chemotherapy combinations to chemotherapy-free regimens: a review. JAMA Oncol. 2022;8(9):1340–1348. doi:10.1001/jamaoncol.2022.2398
   PubMed Web of Science ®Google Scholar
• Tachibana T, Koyama S, Andou T, et al. Salvage and bridging to allogeneic hematopoietic cell transplantation with ponatinib in patients with relapsed or refractory Philadelphia chromosome-positive leukemia. Int J Hematol. 2019;109(2):162–168. doi:10.1007/s12185-018-02571-0
   PubMed Web of Science ®Google Scholar
• Nanno S, Matsumoto K, Nakamae M, et al. Effect of prophylactic post-transplant ponatinib administration on outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2020;20(12):813–819.e1. doi:10.1016/j.clml.2020.07.005
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–753. doi:10.1056/NEJMoa1509277
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Ribera JM, Kantarjian HM, et al. Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia. Cancer. 2020;126(2):304–310. doi:10.1002/cncr.32558
   PubMed Web of Science ®Google Scholar
• Tachibana T, Tanaka M, Hagihara M, et al. Outcomes in patients with acute lymphoblastic leukemia who underwent second allogeneic hematopoietic cell transplantation for relapse after first transplantation. Int J Hematol. 2022;116(4):594–602. doi:10.1007/s12185-022-03377-x
   PubMed Web of Science ®Google Scholar
• Short NJ, Macaron W, Konopleva M, et al. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol. 2022;97(6):E201–E204. doi:10.1002/ajh.26526
   PubMed Web of Science ®Google Scholar
• Park JH, Rivière I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–459. doi:10.1056/NEJMoa1709919
   PubMed Web of Science ®Google Scholar
• Leahy AB, Devine KJ, Li Y, et al. Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy. Blood. 2022;139:2173–2185. doi:10.1182/blood.2021012727
   PubMed Web of Science ®Google Scholar
• Gu B, Shi BY, Zhang X, et al. Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells. Bone Marrow Transplant. 2021;56(1):91–100. doi:10.1038/s41409-020-0982-6
   PubMed Web of Science ®Google Scholar
• Yao Z, Gu B, Zhang Y, et al. CD19 chimeric antigen receptor T-cell therapy as a bridge therapy for allogeneic hematopoietic stem cell transplantation in patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant. 2023;58(1):103–105. doi:10.1038/s41409-022-01845-w
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517. doi:10.1056/NEJMoa1407222
   PubMed Web of Science ®Google Scholar
• Mohty M, Malard F, Blaise D, et al. Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia. Haematologica. 2017;102:184–191. doi:10.3324/haematol.2016.150326
   PubMed Web of Science ®Google Scholar
• Schmid C, Schleuning M, Ledderose G, et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23(24):5675–5687. doi:10.1200/JCO.2005.07.061
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schmid C. The FLAMSA concept-past and future. Ann Hematol. 2020;99(9):1979–1988. doi:10.1007/s00277-020-04131-1
   PubMed Web of Science ®Google Scholar
• Arita K, Kondo T, Sugita J, et al. Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia. Int J Hematol. 2011;94(3):291–295. doi:10.1007/s12185-011-0919-3
   PubMed Web of Science ®Google Scholar
• Bazarbachi AH, Al Hamed R, Labopin M, et al. Allogeneic stem-cell transplantation with sequential conditioning in adult patients with refractory or relapsed acute lymphoblastic leukemia: a report from the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2020;55(3):595–602. doi:10.1038/s41409-019-0702-2
   PubMed Web of Science ®Google Scholar
• Koh K, Ogawa C, Okamoto Y, et al. Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan. Int J Hematol. 2016;104:245–255. doi:10.1007/s12185-016-2004-4
   PubMed Web of Science ®Google Scholar
• Hijiya N, Gaynon P, Barry E, et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia. 2009;23:2259–2264. doi:10.1038/leu.2009.185
   PubMed Web of Science ®Google Scholar
• Saito T, Hatta Y, Hayakawa F, et al. Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group. Int J Hematol. 2021;113(3):395–403. doi:10.1007/s12185-020-03032-3
   PubMed Web of Science ®Google Scholar
• Tachibana T, Kanda J, Ishizaki T, et al. Outcomes and prognostic factors for patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter analysis. Biol Blood Marrow Transplant. 2020;26(5):998–1004. doi:10.1016/j.bbmt.2020.01.007
   PubMed Web of Science ®Google Scholar
• Tachibana T, Kanda J, Ishizaki T, et al. Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis. Ann Hematol. 2021;100(11):2763–2771. doi:10.1007/s00277-021-04607-8
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Kanda Y, Konuma T, et al. Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation. Bone Marrow Transplant. 2022;57(1):43–50. doi:10.1038/s41409-021-01485-6
   PubMedGoogle Scholar
• Yaniv I, Krauss AC, Beohou E, et al. Second hematopoietic stem cell transplantation for post-transplantation relapsed acute leukemia in children: a retrospective EBMT-PDWP study. Biol Blood Marrow Transplant. 2018;24(8):1629–1642. doi:10.1016/j.bbmt.2018.03.002
   PubMed Web of Science ®Google Scholar
• Ferra Coll C, Morgades de la Fe M, Prieto García L, et al. Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation. Eur J Haematol. 2023;110(6):659–668.
   PubMed Web of Science ®Google Scholar